Biden Administration Expecting 200 million Vaccine Doses From Moderna (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE)

The US president Joe Biden has indicated that they have finalized the deal with Moderna (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) for 200 million COVID-19 vaccine doses. President Biden said that these doses will be adequate to vaccinate almost all Americans.

The US expecting 200 million additional COVID-19 vaccine doses

During his visit to the National Institutes of Health, the president said that the federal government had finalized contracts with the companies to supply 100 million doses each. Last Month Biden indicated that he was directing the federal government to secure additional doses besides the 400 million doses ordered under the Trump administration. Biden said that with the new order, the country will have an adequate supply of the two vaccines to inoculate up to 300 million people.

However, it is unclear when everyone in need of the vaccine will get the shot, considering the vaccine administration’s logistical challenges. Biden said that Moderna and Pfizer were accelerating production to deliver around 100 million doses each by May, a month earlier than previously planned. Interestingly, the 200 million additional doses will only be available at the end of July. During his NIH labs tour, the president told reporters that the country is in a good position and will not wait until the end of the summer to deliver vaccines.

The US expects 600 million vaccine doses by the end of summer

According to a White House official, the federal government is expecting around 600 million doses by the end of the summer, but it could take longer to get the doses into patient’s arms. White House is yet to give a timeline for vaccination beyond the 100 million doses promised to deliver Biden’s 100 days in office. President Biden’s administration has been ramping up vaccine supply, and since his inauguration, they have increased distribution by 28%. Biden had indicated that his transition team was made to believe that slow vaccine rollout was a distribution issue rather than a vaccine availability issue, which was not true.